Varian's planning software gets US FDA go-ahead:
This article was originally published in Clinica
Varian Medical Systems has received US FDA 510(k) clearance to market its image-based, three-dimensional treatment planning software BrachyVision 6.0. The software is used to develop plans for low-dose rate brachytherapy as well as temporary implants of radiation sources for high-dose rate brachytherapy in patients with cancer of the cervix, lung, prostate, breast and head and neck, said the Palo Alto, California-based company.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.